isotretinoin and Lymphoma

Epitheliotropic lymphoma is an uncommon cutaneous malignancy of T lymphocytes. Limited information is available regarding the treatment and outcome of dogs with this disease.. To evaluate the treatment outcome and toxicity profile of isotretinoin in dogs with epitheliotropic lymphoma.. Twelve dogs with a diagnosis of epitheliotropic lymphoma were included.. A medical database was searched for dogs diagnosed with epitheliotropic lymphoma and treated with isotretinoin between 2010 and 2021. Diagnosis, treatment details and tumour response were recorded for 12 dogs.. All lesions resolved in four of 12 (33%) treated dogs. Lesions visibly improved in a further three dogs, giving a response rate of 58%. Two dogs' lesions remained unchanged and three progressed despite therapy. Adverse effects occurred in three dogs (25%), all of which were rapidly resolving or not affecting quality of life.. Isotretinoin treatment was a well-tolerated and effective treatment for canine epitheliotropic lymphoma.. Contexte - Le lymphome épithéliotrope est une tumeur maligne cutanée peu fréquente des lymphocytes T. Peu d’informations sont disponibles concernant le traitement et les résultats des chiens atteints de cette maladie. Objectifs - Évaluer les résultats du traitement et le profil de toxicité de l'isotrétinoïne chez les chiens atteints de lymphome épithéliotrope. Animaux - Douze chiens avec un diagnostic de lymphome épithéliotrope ont été inclus. Matériels et méthodes - Une base de données médicale a été recherchée pour les chiens diagnostiqués avec un lymphome épithéliotrope et traités à l'isotrétinoïne entre 2010 et 2021. Le diagnostic, les détails du traitement et la réponse tumorale ont été enregistrés pour 12 chiens. Résultats - Toutes les lésions ont disparu chez quatre des 12 (33 %) chiens traités. Les lésions se sont visiblement améliorées chez trois autres chiens, donnant un taux de réponse de 58 %. Les lésions de deux chiens sont restées stables et trois ont progressé malgré la thérapie. Des effets indésirables sont survenus chez trois chiens (25 %), qui se résolvaient tous rapidement ou n'affectaient pas la qualité de vie. Conclusion - Le traitement à l'isotrétinoïne a été un traitement bien toléré et efficace du lymphome épithéliotrope canin.. Introducción - El linfoma epiteliotrópico es una neoplasia maligna cutánea poco frecuente de linfocitos T. Se dispone de información limitada sobre el tratamiento y el resultado del mismo en perros con esta enfermedad. Objetivos- evaluar el resultado del tratamiento y el perfil de toxicidad de la isotretinoína en perros con linfoma epiteliotrópico. Animales- se incluyeron 12 perros con diagnóstico de linfoma epiteliotrópico. Materiales y métodos- se buscó en una base de datos médica perros diagnosticados con linfoma epiteliotrópico y tratados con isotretinoína entre 2010 y 2021. Se reciplaron datos del diagnóstico, los detalles del tratamiento y la respuesta del tumor en 12 perros. Resultados- todas las lesiones se resolvieron en cuatro de 12 (33 %) perros tratados. Las lesiones mejoraron visiblemente en otros tres perros, con una tasa de respuesta del 58%. Las lesiones de dos perros permanecieron estables y tres progresaron a pesar de la terapia. Efectos adversos fueron reportados en tres perros (25%), todos los cuales se resolvieron rápidamente o no afectaron a la calidad de vida. Conclusión- el tratamiento con isotretinoína fue bien tolerado y eficaz para el linfoma epiteliotrópico canino.. Hintergrund - Das epitheliotrope Lymphom ist eine seltene kutane Malignität von T Lymphozyten. Es gibt nur wenig Information in Bezug auf die Behandlung und den Ausgang dieser Erkrankung bei Hunden. Ziele - Eine Evaluierung des Behandlungserfolges und der Toxizitätsprofile von Isotretinoin bei Hunden mit epitheliotropem Lymphom. Tiere - Zwölf Hunde mit der Diagnose eines epitheliotropen Lymphoms wurden inkludiert. Materialien und Methoden - Eine medizinische Datenbank wurde auf Hunde, die zwischen 2010 und 2021 mit einem epitheliotropen Lymphom diagnostiziert und mit Isotretinoin behandelt worden waren, durchsucht. Die Diagnose, die Behandlungsdetails und die Tumorantwort wurden bei 12 Hunden festgehalten. Ergebnisse - Alle Läsionen verschwanden bei vier von 12 (33%) behandelten Hunden. Bei drei weiteren Hunden verbesserten sich die Läsionen sichtlich, was eine Antwortrate von 58% ergab. Bei zwei Hunden blieben die Veränderungen stabil und bei drei Hunden schritten sie trotz Behandlung voran. Nebenwirkungen traten bei drei Hunden (25%) auf, von denen alle rasch wieder verschwanden und die Lebensqualität nicht weiter beeinflussten. Schlussfolgerung - Isotretinoin war eine gut tolerierte und wirksame Behandlung bei Hunden mit epitheliotropem Lymphom.. 背景 - 上皮向性リンパ腫は、Tリンパ球皮膚悪性腫瘍でまれな疾患である。本疾患の治療および転帰に関する情報は限られている。 目的 - 本研究の目的は、上皮向性リンパ腫の犬におけるイソトレチノインの治療成績および毒性プロファイルを評価することであった。 供試動物 - 上皮向性リンパ腫と診断された犬 12 頭を対象とした。 材料と方法 - 2010年から2021年の間に上皮向性リンパ腫と診断され、イソトレチノインで治療された犬を医療データベースで検索した。12 頭の犬について、診断、治療の詳細、腫瘍の反応を記録した。 結果 - 治療を受けた 12 頭中 4 頭 (33%) ですべての病変が消失した。さらに3頭の犬で病変が目に見えて改善し、奏効率は58%であった。2 頭は病変が安定し、3 頭は治療にもかかわらず進行した。副作用は3頭 (25%) に発現したが、いずれも速やかに消失し、QOLに影響を与えることはなかった。 結論 - イソトレチノイン治療は、犬の上皮性リンパ腫に対して忍容性が高く、有効な治療法であった。.. 背景-趋上皮性淋巴瘤是一种不常见的T淋巴细胞皮肤恶性肿瘤。关于该疾病犬的治疗和结局的可用信息有限。 目的-评价异维A酸在趋上皮性淋巴瘤犬中的治疗结局和毒性特征。 纳入动物-12只诊断为趋上皮性淋巴瘤的犬。 材料和方法-检索了2010年至2021年间诊断为趋上皮性淋巴瘤,并接受异维A酸治疗的犬的医学数据库。记录了12只犬的诊断、治疗详情和肿瘤反应。 结果-4/12(33%)只治疗犬的所有病变均消退。另外3只犬的病变明显改善, 缓解率为58%。尽管接受了治疗, 但2只犬的病变保持稳定, 3只继续发展。3只犬(25%)出现不良反应, 均迅速消退或不影响生活质量。 结论-异维A酸治疗犬趋上皮性淋巴瘤是一种耐受性良好且有效的治疗方法。.. Contexto - O linfoma epiteliotrópico é uma neoplasia cutânea de linfócitos T incomum. As informações disponíveis sobre o tratamento e evolução de cães com essa doença são limitadas. Objetivos - Avaliar a resposta ao tratamento e o perfil de toxicidade da isotretinoína em cães com linfoma epiteliotrópico. Animais - Doze cães com linfoma epiteliotrópico foram incluídos. Materiais e métodos - Pesquisou-se em um banco de dados médico os cães diagnosticados com linfoma epiteliotrópico e tratados com isotretinoína entre 2010 e 2021. Diagnóstico, detalhes do tratamento e resposta tumoral foram registrados para 12 cães. Resultados - Todas as lesões se resolveram em quatro de 12 (33%) cães. As lesões melhoraram visivelmente em outros três cães, gerando uma taxa de resposta de 58%. As lesões de dois cães permaneceram estáveis e três progrediram apesar da terapia. Ocorreram efeitos adversos em três cães (25%), mas todos apresentaram resolução rápida ou não tiveram alteração na qualidade de vida. Conclusão - O tratamento com isotretinoína foi bem tolerado e eficaz para o linfoma epiteliotrópico canino.

Topics: Animals; Dog Diseases; Dogs; Isotretinoin; Lymphoma; Quality of Life; Skin Neoplasms

Apoptosis is a form of regulated cell death that plays an important role in the maintenance of tissue homeostasis. Treatment of Dalton's lymphoma ascites cells (DLA)-induced experimental solid tumor tumor cells with 13 cis-retinoic acid, at concentrations of 25 microg/mL and 50 microg/mL, produced apoptotic morphologic changes, such as nuclear condensation and DNA-ladder formation after 48h incubation at 37 degrees C. in addition, the compound upregulated caspase-3 expression and downregulated bcl-2 gene expression. In vivo treatment with 13 cis-retinoic acid (200 micromoles/kg body weight, ip) inhibited solid tumor development induced with DLA cells in Swiss albino mice. In conclusion, the results suggest that the anti-tumor activity of 13 cis-retinoic acid in DLA cells is due to apoptosis mediated by the regulation of bcl-2 and caspase-3 gene expression.

Topics: Animals; Apoptosis; Ascites; Caspase 3; Cell Line, Tumor; Cell Nucleus; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Injections, Intraperitoneal; Injections, Subcutaneous; Isotretinoin; Lymphoma; Male; Mice; Neoplasms, Experimental; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction

We recently reported the successful use of retinoic acids in the treatment of refractory lymphoma. The biologic determinants predicting response of lymphomas to retinoic acid remain unknown. This study was conducted to explore this question using in vitro models. Sensitivity of representative lymphoma cells to 13-cis-retinoic acid was determined. Sensitive and resistant cell lines were then compared for their baseline and/or retinoic-acid-regulated expression of total cellular retinoic acid binding protein, retinoic acid receptor (RAR)-alpha, RAR-beta, RAR-gamma mRNA, retinoid X receptor (RXR)-alpha, RXR-beta, RXR-gamma mRNA, transforming growth factor (TGF)-beta 1 and TGF-beta 1 receptors, and Fas (Apo-I) mRNA. The results showed that four of five T, two of three Hodgkin's, and none of six B cell lymphoma cell lines were sensitive (IC30 < 1.5 mmol/L) to 13-cis-retinoic acid. Further analyses revealed several of the above-mentioned parameters may be relevant to retinoic acid sensitivity. Baseline expression of TGF-beta 1 receptors was present in all of the five sensitive cell lines examined, but in only one of the four resistant cell lines. The correlation of Fas expression and retinoic acid sensitivity was good for B cell lines, but not apparent for T cell or Hodgkin's cell lines. On exposure to retinoic acid, an immediate and prolonged upregulation of RAR-alpha mRNA expression, lasting for more than 12 hours, occurred in all sensitive cell lines, but only minimal or transient induction was seen in resistant cells. Together, these data suggested that; 1) retinoic acid has a preferential effect on T cell and Hodgkin's lymphoma cell lines; 2) autoregulation of RAR-alpha by retinoic acids, and the presence of TGF-beta 1 receptors may be relevant to the response of lymphomas to treatment with retinoic acids.

Topics: Drug Screening Assays, Antitumor; fas Receptor; Humans; Isotretinoin; Lymphoma; Receptors, Retinoic Acid; Receptors, Transforming Growth Factor beta; Tumor Cells, Cultured

An 8-year-old spayed female ferret was examined for diffuse generalized alopecia, erythema, erosions, crusts, and ulcerated plaques that were nonresponsive to long-term administration of corticosteroids. Cutaneous epitheliotropic lymphoma was diagnosed on the basis of histologic examination of skin biopsy specimens. Neoplastic cells were determined to be of T-lymphocytic origin by results of immunohistochemical staining with a rabbit anti-CD3 monoclonal antibody. Additional laboratory abnormalities detected included anemia, azotemia, isosthenuria, pyuria, and bacteriuria. Treatment included isotretinoin and amoxicillin trihydrate plus clavulanate potassium administered orally, and oatmeal-based shampoos. Isotretinoin was tolerated well and cutaneous lesions resolved after 60 days of treatment, but pretreatment azotemia worsened and the ferret was euthanatized. Necropsy revealed cutaneous epitheliotropic lymphoma, pyelonephritis, and interstitial nephritis. Renal disease most likely was caused by immunosuppression secondary to chronic treatment with corticosteroids and aging. Isotretinoin, although not curative, may be useful for the palliative treatment of cutaneous epitheliotropic lymphoma in ferrets.

Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Clavulanic Acid; Clavulanic Acids; Combined Modality Therapy; Dietary Proteins; Female; Ferrets; Isotretinoin; Keratolytic Agents; Lymphoma; Penicillins; Skin Neoplasms

The purpose of this study was to evaluate the synthetic retinoids isotretinoin and etretinate to treat dogs with intracutaneous cornifying epitheliomas (ICE), other benign skin neoplasias, and cutaneous lymphoma. Twenty-four dogs were used. All tumors were diagnosed by histologic examination. Ten dogs with multiple (at least 5) benign skin tumors (7 with ICE, 1 each with inverted papillomas, sebaceous adenomas and epidermal cysts) were treated with isotretinoin (n = 7) and/or etretinate (n = 5). Twelve dogs with cutaneous lymphoma were treated with isotretinoin, and 2 dogs with cutaneous lymphoma were initially treated with etretinate. Successful treatment with isotretinoin was achieved in 1 dog with ICE, 1 with inverted papillomas, and 1 with epidermal cysts. Partial improvement with isotretinoin was seen in 2 dogs with ICE. Successful treatment was achieved with etretinate in 4 dogs with ICE (Norwegian Elkhound was the predominant breed with ICE). Remission was achieved in 6 of the 14 dogs with cutaneous lymphoma. Adverse effects developed in 7 of the 24 dogs, so treatment was stopped in 2 dogs.

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dog Diseases; Dogs; Etretinate; Isotretinoin; Lymphoma; Skin Neoplasms

Sixteen patients - 12 with cutaneous T cell lymphoma (CTCL), 1 with Sézary syndrome, 1 with actinic reticuloid, and 2 with parapsoriasis variegata - were treated with either a new, potent arotinoid alone or with combined etretinate (Tigason) and PUVA therapy (Re-PUVA). 92% of all patients showed a minor up to a distinct response of their skin lesions within 12.6 +/- 7.4 weeks. More than 50% of the skin lesions cleared in 67% of the patients. After discontinuation of the retinoid therapy, relapses occurred in all cases within 3-10 weeks. There was no difference between the therapeutic efficacy of arotinoid alone and the Re-PUVA regimen, but the latter was less toxic.

Topics: Antineoplastic Agents; Benzoates; Combined Modality Therapy; Humans; Isotretinoin; Lymphoma; PUVA Therapy; Retinoids; Skin Neoplasms; T-Lymphocytes; Tretinoin

The aim of the study was to analyze the incidence of spontaneous thymic lymphomas in AKR mice kept on a diet with normal and excess retinoid content. The mice whose diet was supplemented with 13-cis-retinoic acid (250 mg per kg chow) developed less lymphomas than those kept on a standard diet (15 mg per kg chow). The effect of cyclophosphamide on the early stage of lymphomogenesis was tested using a single dose (100 mg per kg body weight), injected intraperitoneally to AKR mice. Increased incidence of lymphoma following cyclophosphamide administration was observed as result of a) low sensitivity of prelymphoma and lymphoma cells and/or b) immunosuppressive effect of cyclophosphamide.

Topics: Animals; Cocarcinogenesis; Cyclophosphamide; Diet; Female; Injections, Intraperitoneal; Isotretinoin; Lymphoma; Male; Mice; Thymus Neoplasms; Tretinoin

The aim of the study was to analyze the incidence of X-ray induced lymphomas in C57B1/10W mice kept on diet with varying retinoid content. The mice whose diet was supplemented with 13-cis retinoic acid (300 mg per kg of chow) developed less lymphomas than those kept on Vitamin A deficient diet as well as on a standard diet (15 mg per kg of chow). Mice subjected to Vitamin A deficient diet displayed a shortening of the latency period.

Topics: Administration, Oral; Animals; Female; Isotretinoin; Leukemia, Radiation-Induced; Lymphoma; Mice; Mice, Inbred Strains; Thymus Neoplasms; Tretinoin

Topics: Humans; Isotretinoin; Lymphoma; Skin Neoplasms; T-Lymphocytes; Tretinoin